GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Vitrolife AB (CHIX:VITRs) » Definitions » EV-to-EBIT

Vitrolife AB (CHIX:VITRS) EV-to-EBIT : -6.88 (As of Jun. 23, 2024)


View and export this data going back to 2016. Start your Free Trial

What is Vitrolife AB EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Vitrolife AB's Enterprise Value is kr24,813 Mil. Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-3,608 Mil. Therefore, Vitrolife AB's EV-to-EBIT for today is -6.88.

The historical rank and industry rank for Vitrolife AB's EV-to-EBIT or its related term are showing as below:

CHIX:VITRs' s EV-to-EBIT Range Over the Past 10 Years
Min: -7.86   Med: 39.68   Max: 152.15
Current: -6.88

During the past 13 years, the highest EV-to-EBIT of Vitrolife AB was 152.15. The lowest was -7.86. And the median was 39.68.

CHIX:VITRs's EV-to-EBIT is ranked worse than
100% of 450 companies
in the Medical Devices & Instruments industry
Industry Median: 19.075 vs CHIX:VITRs: -6.88

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Vitrolife AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr24,016 Mil. Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 was kr-3,608 Mil. Vitrolife AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -15.02%.


Vitrolife AB EV-to-EBIT Historical Data

The historical data trend for Vitrolife AB's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vitrolife AB EV-to-EBIT Chart

Vitrolife AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 42.08 61.15 165.36 46.25 -7.63

Vitrolife AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 50.64 48.39 34.28 -7.63 -7.86

Competitive Comparison of Vitrolife AB's EV-to-EBIT

For the Medical Devices subindustry, Vitrolife AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vitrolife AB's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Vitrolife AB's EV-to-EBIT falls into.



Vitrolife AB EV-to-EBIT Calculation

Vitrolife AB's EV-to-EBIT for today is calculated as:

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=24812.714/-3608
=-6.88

Vitrolife AB's current Enterprise Value is kr24,813 Mil.
Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3,608 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vitrolife AB  (CHIX:VITRs) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Vitrolife AB's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Mar. 2024 ) =EBIT / Enterprise Value (Q: Mar. 2024 )
=-3608/24015.543
=-15.02 %

Vitrolife AB's Enterprise Value for the quarter that ended in Mar. 2024 was kr24,016 Mil.
Vitrolife AB's EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was kr-3,608 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vitrolife AB EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Vitrolife AB's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Vitrolife AB (CHIX:VITRS) Business Description

Traded in Other Exchanges
Address
Box 9080, Gothenburg, SWE, 400 92
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive advanced support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction.

Vitrolife AB (CHIX:VITRS) Headlines

No Headlines